Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

y (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual r
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... Oxybutynin Hydrochloride Industry, 2009-2019 is a professional ... Chinese Oxybutynin Hydrochloride industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Oxybutynin Hydrochloride listing their ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... Novavax, Inc.,(Nasdaq: NVAX ) announced today ... trial of its non-adjuvanted pandemic influenza virus-like,particle (VLP) ... Officer and Head of Clinical,Development stated, "The initial ... support further development of our pandemic influenza vaccine,through ...
... announce the,recent publication of important results from research into ... compounds, C75. The,Company is a leader in the research ... area of that research has been for the treatment,of ... is centered in the hypothalamus in the brain, research ...
Cached Medicine Technology:Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 4FASgen Announces New Discovery for Treatment of Stroke 2
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... -- More states are passing legislation permitting or requiring ... any child having a severe allergic reaction. Epinephrine ... reaction that can lead to throat swelling, breathing difficulties, ... In people with severe allergies to certain ... or certain drugs, anaphylaxis can occur within moments of ...
(Date:9/19/2014)... September 19, 2014 Top 10 ... recently announced that HostGator.com, GoDaddy and Bluehost are ... These companies are the most recommended suppliers for ... Europe to buy high quality Linux hosting (including ... ) is one of many top hosting companies ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:A better way to track emerging cell therapies using MRIs 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2
... Inc's brand cleansing solution has been linked to a severe ... Optometry doctors in the U.S have urged contact lens wearers ... Bausch & Lomb Inc. has stopped shipping ... following warnings from the U.S. Food and Drug Administration (FDA) ...
... than 1lb 6oz. He was so weak that he needed life ... he lived and grew stronger. //Even his mother Donna Morgan who ... be given blood transfusions to recover. ,Now the mother ... helped them, they are launching a campaign to fill the worryingly ...
... from far but far from good! A city that has ... life// , might not be promoting feelings of well-being in ... happen to be a highly distressed lot compared to the ... cause of distress, opining that nearly one out of seven ...
... Ontario plans to revamp the drug system. Health Minister ... to improve the drug program//. He also said that ... drug system transparent and sustainable. They will also speed ... voices are heard. The taxpayers have not received fair ...
... in the April issue of IJCP, the International Journal ... of cases of invasive// pneumococcal diseases (IPD) like meningitis ... still only vaccinate selected at-risk groups against IPD. ... vaccination of infants and young children reduces their risk ...
... obesity is due at least in part to an ... when to stop eating, and a protein more recently// ... protein (CRP) not only binds to leptin but its ... The results may help explain why obese people have ...
Cached Medicine News:Health News:Promotion of Pneumococcal Vaccine Slow in Europe 2Health News:Promotion of Pneumococcal Vaccine Slow in Europe 3Health News:Researchers Identify The Cause To Obesity 2Health News:Researchers Identify The Cause To Obesity 3
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... Clopidogrel Assay measures changes in platelet ... Clopidogrel (Plavix). It uses a specific ... clopidogrel inhibits. The assay has not ... the assay is available for Research ...
Medicine Products: